FI73993C - Foerfarande foer framstaellning av radioaktivt maerkta 8-/4-/4-(2-pyrimidinyl)-1-piperazinyl/butyl/-8- azaspiro/4.5/dekan-7,9-dioner. - Google Patents
Foerfarande foer framstaellning av radioaktivt maerkta 8-/4-/4-(2-pyrimidinyl)-1-piperazinyl/butyl/-8- azaspiro/4.5/dekan-7,9-dioner. Download PDFInfo
- Publication number
- FI73993C FI73993C FI813937A FI813937A FI73993C FI 73993 C FI73993 C FI 73993C FI 813937 A FI813937 A FI 813937A FI 813937 A FI813937 A FI 813937A FI 73993 C FI73993 C FI 73993C
- Authority
- FI
- Finland
- Prior art keywords
- piperazinyl
- azaspiro
- butyl
- dione
- pyrimidinyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 17
- -1 4- (2-PYRIMIDINYL) -1-PIPERAZINYL Chemical class 0.000 title claims description 13
- 230000002285 radioactive effect Effects 0.000 title claims description 4
- 238000012423 maintenance Methods 0.000 title 1
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 15
- WTVNFKVGGUWHQC-UHFFFAOYSA-N decane-2,4-dione Chemical compound CCCCCCC(=O)CC(C)=O WTVNFKVGGUWHQC-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 239000000460 chlorine Chemical group 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 229910052801 chlorine Chemical group 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000011630 iodine Chemical group 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 239000012442 inert solvent Substances 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 7
- 229960002495 buspirone Drugs 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical group ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 2
- 150000005695 2-halopyrimidines Chemical class 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 101100520660 Drosophila melanogaster Poc1 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101100520662 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PBA1 gene Proteins 0.000 description 1
- YBGJZYCWGNYUMA-UHFFFAOYSA-M [Cl-].[P+]=O Chemical compound [Cl-].[P+]=O YBGJZYCWGNYUMA-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VXDSLUMUNWTSDB-UHFFFAOYSA-N acetic acid;chloroform;methanol Chemical compound OC.CC(O)=O.ClC(Cl)Cl VXDSLUMUNWTSDB-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- YRTHJMQKDCXPAY-UHFFFAOYSA-N azaspirodecanedione Chemical compound C1C(=O)NC(=O)CC11CCCC1 YRTHJMQKDCXPAY-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- YJIRDHXJRYYJHD-UHFFFAOYSA-N decane-2,4-dione;hydrochloride Chemical compound Cl.CCCCCCC(=O)CC(C)=O YJIRDHXJRYYJHD-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21521480A | 1980-12-11 | 1980-12-11 | |
| US21521480 | 1980-12-11 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI813937L FI813937L (fi) | 1982-06-12 |
| FI73993B FI73993B (fi) | 1987-08-31 |
| FI73993C true FI73993C (fi) | 1987-12-10 |
Family
ID=22802113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI813937A FI73993C (fi) | 1980-12-11 | 1981-12-08 | Foerfarande foer framstaellning av radioaktivt maerkta 8-/4-/4-(2-pyrimidinyl)-1-piperazinyl/butyl/-8- azaspiro/4.5/dekan-7,9-dioner. |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS57122082A (fr) |
| AT (1) | AT380686B (fr) |
| AU (1) | AU528067B2 (fr) |
| BE (1) | BE891446A (fr) |
| CA (1) | CA1172255A (fr) |
| CH (1) | CH647518A5 (fr) |
| DE (1) | DE3149011A1 (fr) |
| DK (1) | DK154560C (fr) |
| FI (1) | FI73993C (fr) |
| FR (1) | FR2496105B1 (fr) |
| GB (1) | GB2089341B (fr) |
| GR (1) | GR76331B (fr) |
| IE (1) | IE51948B1 (fr) |
| IT (1) | IT1172073B (fr) |
| LU (1) | LU83833A1 (fr) |
| NL (1) | NL8105529A (fr) |
| SE (1) | SE444438B (fr) |
| YU (1) | YU42432B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU212301B (en) * | 1989-04-28 | 1996-05-28 | Alkaloida Vegyeszeti Gyar | Process for producing buspirone |
| US5484788A (en) * | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
| US5631017A (en) * | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
| KR950014099A (ko) * | 1993-11-10 | 1995-06-15 | 장기하 | N-(2-피리미딜)피페라지닐 부틸아미드의 제조방법 |
| US5637314A (en) * | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759371A (fr) * | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
| DE2341925A1 (de) * | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
-
1981
- 1981-09-29 CA CA000386889A patent/CA1172255A/fr not_active Expired
- 1981-10-05 AU AU76041/81A patent/AU528067B2/en not_active Expired
- 1981-10-09 YU YU2436/81A patent/YU42432B/xx unknown
- 1981-10-27 GB GB8132370A patent/GB2089341B/en not_active Expired
- 1981-11-16 IT IT49718/81A patent/IT1172073B/it active
- 1981-11-27 GR GR66636A patent/GR76331B/el unknown
- 1981-12-08 FR FR8122916A patent/FR2496105B1/fr not_active Expired
- 1981-12-08 CH CH7842/81A patent/CH647518A5/de not_active IP Right Cessation
- 1981-12-08 NL NL8105529A patent/NL8105529A/nl active Search and Examination
- 1981-12-08 FI FI813937A patent/FI73993C/fi not_active IP Right Cessation
- 1981-12-09 JP JP56197037A patent/JPS57122082A/ja active Granted
- 1981-12-10 DE DE19813149011 patent/DE3149011A1/de active Granted
- 1981-12-10 DK DK548081A patent/DK154560C/da not_active IP Right Cessation
- 1981-12-10 AT AT0529581A patent/AT380686B/de not_active IP Right Cessation
- 1981-12-10 IE IE2897/81A patent/IE51948B1/en not_active IP Right Cessation
- 1981-12-11 LU LU83833A patent/LU83833A1/fr unknown
- 1981-12-11 SE SE8107446A patent/SE444438B/sv not_active IP Right Cessation
- 1981-12-11 BE BE0/206810A patent/BE891446A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IT1172073B (it) | 1987-06-18 |
| JPH0113476B2 (fr) | 1989-03-06 |
| CH647518A5 (de) | 1985-01-31 |
| DK154560C (da) | 1989-04-17 |
| DE3149011A1 (de) | 1982-07-15 |
| GB2089341B (en) | 1984-09-19 |
| AT380686B (de) | 1986-06-25 |
| AU7604181A (en) | 1982-07-15 |
| SE8107446L (sv) | 1982-06-12 |
| SE444438B (sv) | 1986-04-14 |
| LU83833A1 (fr) | 1982-07-07 |
| IE812897L (en) | 1982-06-11 |
| BE891446A (fr) | 1982-06-11 |
| IT8149718A0 (it) | 1981-11-16 |
| AU528067B2 (en) | 1983-04-14 |
| JPS57122082A (en) | 1982-07-29 |
| FI813937L (fi) | 1982-06-12 |
| GB2089341A (en) | 1982-06-23 |
| DK154560B (da) | 1988-11-28 |
| FR2496105B1 (fr) | 1985-12-13 |
| DK548081A (da) | 1982-06-12 |
| NL8105529A (nl) | 1982-07-01 |
| YU243681A (en) | 1984-02-29 |
| CA1172255A (fr) | 1984-08-07 |
| GR76331B (fr) | 1984-08-04 |
| FR2496105A1 (fr) | 1982-06-18 |
| ATA529581A (de) | 1985-11-15 |
| DE3149011C2 (fr) | 1988-08-25 |
| IE51948B1 (en) | 1987-04-29 |
| YU42432B (en) | 1988-08-31 |
| FI73993B (fi) | 1987-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR870001045B1 (ko) | 2-[4-[(4,4-디알킬-2,6-피페리딘디온-1-일)부틸]피페라지닐] 피리미딘류의 제조방법 | |
| RU2096411C1 (ru) | Производные бензимидазолона, смеси их изомеров или их кислотно-аддитивные соли в качестве антагониста рецептора 5-ht*00i*00a и 5-нт*002 | |
| CN103333156B (zh) | 一种2-取代芳乙烯基-n-甲基化喹啉衍生物的制备及其在抗阿尔兹海默症药物中的应用 | |
| US20090030062A1 (en) | Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine d3 receptors | |
| CA2684563C (fr) | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines et pyridines et 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines comme antagonistes de recepteur 5-ht<sb>7 </sb> | |
| US4882432A (en) | Polycyclic-carbamic acid piperazinoalkyl esters and amides | |
| DK148481B (da) | Azaspiro-kvarternaere ammoniumhalogenide og en fremgangsmaade, ved hvilken disse anvendes til fremstilling af n-(2-pyrimidinyl)-piperazinylalkylazaspiroalkandioner | |
| CA1327577C (fr) | Derives 6-phenyl-3-(piperazinylalkyl)-2,4(1h,3h) pyrimidinedione, leur preparation et leur application en therapie | |
| FI73993C (fi) | Foerfarande foer framstaellning av radioaktivt maerkta 8-/4-/4-(2-pyrimidinyl)-1-piperazinyl/butyl/-8- azaspiro/4.5/dekan-7,9-dioner. | |
| EP1194415B1 (fr) | Nouveaux derives de piperazinyl-alkyl-thiopyrimidine compositions pharmaceutiques les contenant et procede de preparation de la substance active | |
| US4305944A (en) | N-[(4-[3-cyano substituted pyridyl]piperazino)alkyl]-azaspirodecanediones | |
| JP2011515359A (ja) | 治療用トリアゾールアミド誘導体 | |
| El-Tombary et al. | Novel triazolo [4, 3-a] quinazolinone and bis-triazolo [4, 3-a: 4, 3′-c] quinazolines: synthesis and antitoxoplasmosis effect | |
| FI85484B (fi) | Foerfarande foer framstaellning av antipsykotiska pyridinylpiperazinderivat som innehaoller en kondenserad ring. | |
| US4677104A (en) | Antipsychotic fused-ring pyridinylpiperazine derivatives | |
| NZ314347A (en) | Process for the preparation of unsymmetrical 4,6-bis(aryloxy)pyrimidine compounds | |
| JPS59110690A (ja) | ベンゾピラン誘導体 | |
| Takahashi et al. | Preparation of 5‐sulfonylpyrimidines from β‐keto, β‐cyano‐, and β‐ethoxycarbonyl‐β‐sulfonylenamines | |
| Caliendo et al. | Synthesis and binding affinities for 5-HT1A, 5-HT2A and 5-HT2C receptors of a series of 1-and 2-(4-arylpiperazinylalkyl)-4-(benzoyl)-1, 2, 3-triazole derivatives | |
| Takagi et al. | Synthesis of pyrimidino [4, 5‐b][1, 5] benzodiazepin‐2‐ones and pyrimidino [1, 6‐a] benzimidazol‐1‐ones from 4‐ethoxycarbonylamino‐1H‐1, 5‐benzodiazpine‐3‐carbonitrile via 4‐(2‐aminoanilino) pyrimidin‐2 (1H)‐one‐5‐carbonitriles | |
| SEKIYA et al. | Pyrimidine Derivatives. II. New Synthesis and Reactions of 4-Amino-2-methylthiopyrimidine Derivatives | |
| Terentjeva et al. | Synthesis 6-perfluoroalkylpyrimidine analogues of imatinib | |
| Warner Jr et al. | Synthesis of 6-(N-alkyl-N-arylamino) pyrimidines as potential antimetabolites | |
| US2443304A (en) | Halogenopyrimidine derivatives | |
| Gadhave et al. | Synthesis and Antifungal Screening of Novel 1-methyl-2-aminophenyl-4 (N4-alkyl/aryl piperazinyl) benzimidazole Derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |
Owner name: BRISTOL-MYERS CO |